Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94773
Title:
Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.
Authors:
Craft, A W; Cotterill, S J; Bullimore, J A; Pearson, D
Abstract:
The aim of this study was to evaluate multimodal chemotherapy and radiotherapy in patients with Ewing's sarcoma. 142 (74 male, 68 female) patients were entered into the ET-1 study between 1978 and 1986. They were treated with vincristine, doxorubicin, actinomycin D, and cyclophosphamide with radiotherapy plus or minus surgery to the primary tumour. Of the 120 who had no metastases at diagnosis, 45 remain alive with a median follow-up of 11.2 years. Only 2 of those with metastases at diagnosis remain alive. The major prognostic factor was site of disease, but age and serum lactic dehydrogenase at diagnosis also had an influence on outcome. 45 of the 61 patients who survived 4 years or more had late effects documented. The type and extent were dependent on tumour site, type of local therapy, volume and dose of radiotherapy. 4 patients had second malignancies. Prospects for long-term survival have improved in patients treated for Ewing's sarcoma. However, late sequelae are present in the majority of patients.
Affiliation:
Department of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.
Citation:
Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. 1997, 33 (7):1061-9 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Jun-1997
URI:
http://hdl.handle.net/10541/94773
DOI:
10.1016/S0959-8049(97)00043-9
PubMed ID:
9376188
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCraft, A Wen
dc.contributor.authorCotterill, S Jen
dc.contributor.authorBullimore, J Aen
dc.contributor.authorPearson, Den
dc.date.accessioned2010-03-23T17:09:02Z-
dc.date.available2010-03-23T17:09:02Z-
dc.date.issued1997-06-
dc.identifier.citationLong-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. 1997, 33 (7):1061-9 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid9376188-
dc.identifier.doi10.1016/S0959-8049(97)00043-9-
dc.identifier.urihttp://hdl.handle.net/10541/94773-
dc.description.abstractThe aim of this study was to evaluate multimodal chemotherapy and radiotherapy in patients with Ewing's sarcoma. 142 (74 male, 68 female) patients were entered into the ET-1 study between 1978 and 1986. They were treated with vincristine, doxorubicin, actinomycin D, and cyclophosphamide with radiotherapy plus or minus surgery to the primary tumour. Of the 120 who had no metastases at diagnosis, 45 remain alive with a median follow-up of 11.2 years. Only 2 of those with metastases at diagnosis remain alive. The major prognostic factor was site of disease, but age and serum lactic dehydrogenase at diagnosis also had an influence on outcome. 45 of the 61 patients who survived 4 years or more had late effects documented. The type and extent were dependent on tumour site, type of local therapy, volume and dose of radiotherapy. 4 patients had second malignancies. Prospects for long-term survival have improved in patients treated for Ewing's sarcoma. However, late sequelae are present in the majority of patients.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectCancer Recurrenceen
dc.subjectSecond Primary Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshAdolescent-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Neoplasms-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCyclophosphamide-
dc.subject.meshDactinomycin-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshL-Lactate Dehydrogenase-
dc.subject.meshLeg-
dc.subject.meshMale-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeoplasms, Second Primary-
dc.subject.meshProportional Hazards Models-
dc.subject.meshRisk Factors-
dc.subject.meshSarcoma, Ewing's-
dc.subject.meshSurvival Analysis-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshVincristine-
dc.titleLong-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.en
dc.typeArticleen
dc.contributor.departmentDepartment of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.